Found: 6
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2025 · pp. 30–38
Nigmatullina R.R., Sadykova D.I., Salakhova K.R., Slastnikova E.S., Abzaletdinova G.F.
Introduction. Cardiovascular diseases are the main cause of death and disability in the world population. Serotonin plays a significant role in the development and progression of atherosclerotic processes due to its two classical functions – platelet aggregati…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2022 · pp. 34–41
Barinov E.F., Malinin Y.Yu., Grigoryan H.V.
The study aims to analyze the dependence of an α1А-adrenoreceptor antagonist effectiveness on G-protein-coupled receptors (GPCRs) intracellular signaling in the passage of medium-sized calculi from the ureter. Material and methods. The study was prospective an…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2022 · pp. 43–49
Barinov E.F., Grigoryan Kh.V., Malinin Y.Yu.
Аim of the study was to evaluate the activity of receptors that control contraction (α2-adrenergic receptor, purine P2X1 and P2Y receptors, angiotensin AT1 receptor, TxA2 receptor) and relaxation of smooth myocytes (adenosine A2 receptor) during standard litho…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2022 · pp. 45–52
Barinov E.F., Malinin Y.Yu., Grigoryan Kh.V.
The reasons for the low efficiency of the α1A-blockers using in the scheme of lithokinetic therapy (LCT) remain unclear. The aim of the study was to evaluate the activity of the purinergic P2X1 receptor in the blockade of the α1A-adrenergic receptor during LCT…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2015
Alexeev А.А., Brylev M.I., Korolev V.L., Lotorev D.S., Lizunov A.Yu., Zaitseva N.I., Pavlova L.А., Ivshin V.P.
Introduction. Cardiovascular diseases consistently occupy the first place among causes of death and disability in almost all developed countries. The main importance of this group of diseases have myocardial infarction. One of the causes of myocardial infarcti…
Research article2013
Alekseev A.A., Brylev M.I., Korolev V.L., Lotorev D.S., Lizunov A.Yu., Batuev E.A., Pavlova L.A.
We applied software «Algokomb» to perform mathematical modeling of polypeptide molecules of glycoprotein IIb/IIIa (gpIIb/IIIa) receptor antagonists. The modeled compounds have been synthesized accordingly to the protocol of strategy FastMoc 0.25. The structure…